Drug Trial Radar · NCT05813795
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Last checked: Nov 19, 2026Latest source record: Apr 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
664
Actual
Start
Apr 5, 2023
Primary completion
Jun 20, 2024
Study completion Oct 10, 2024
Sponsor
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
Conditions
- Weight Management
Interventions
Ecnoglutide Low DosageDrug
Subcutaneous Injection
Ecnoglutide Medium DosageDrug
Subcutaneous Injection
Ecnoglutide High DosageDrug
Subcutaneous Injection
PlaceboDrug
Subcutaneous Injection with matched volume
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baselineTime frame: Week 40
- Proportion of subjects with weight loss ≥5% from baselineTime frame: Week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.